Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irradiation Stent + TACE vs Sorafenib + TACE in HCC with PVTT
NCT03730675Unknown
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Overall Survival at 36 months. Status: unknown.
Beyond the preview
Go deeper on NCT03730675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730675.